Home/ Technology/ Platforms
Three Technology Platforms

One R&D engine. Three revolutions in patient care.

Our research institute operates three integrated platforms, each addressing a different layer of the human tissue repair problem — from form, to function, to in-situ regeneration.

The Platform Triad

From "fill the hole" to "regenerate the tissue".

Most medtech companies optimise one stage of the repair cascade. Excellent MedTech is unique in operating all three — and integrating them so that today's implant becomes tomorrow's regenerative scaffold.

ME-Fab®

Additive manufacturing of personalised implants

From 30,000+ clinical cases, deep-learning models achieve 95%+ bionic match — shipped as a Class III implant.

  • Electron Beam Melting of Ti-6Al-4V ELI
  • Gradient-optimised porous micro-architecture
  • Patient-specific 1:1 reconstruction
  • Validated for cranial, maxillofacial, orthopaedic
  • NMPA Class III · ISO 13485 · CE-MDR in progress
Explore ME-Fab® →
ME-Regen®

Controlled-release protein engineering

Microgram-level precision protein delivery extends therapeutic retention to 2–4 weeks.

  • Low-dose, long-acting protein release
  • Tunable release kinetics
  • Bone, skin, vascular, neural applications
  • Closed-loop R&D; pilot & clinical coming
  • Patent-protected formulation platform
Explore ME-Regen® →
Cell home®

In-vivo tissue engineering & organ transplant

Building consistent, functional human tissue for transplant — solving donor ethics and shortage.

  • In-vitro and in-vivo tissue manufacturing
  • Bone, cartilage, skin, vascular, neural
  • Eliminates donor-site morbidity
  • Pilot scale; clinical coming
  • Long-term vision of organ replacement
Explore Cell home® →
The Integration

Three platforms. One patient continuum.

ME-Fab®, ME-Regen®, and Cell home® are not parallel programmes. They are layers of the same patient-care continuum — from mechanical reconstruction today, to pharmacologically enhanced regeneration tomorrow, to tissue engineering the day after.

  • Today — ME-Fab® delivers a Class III patient-matched titanium implant with a porous micro-architecture that supports bone ingrowth.
  • Tomorrow — The same implant surface is loaded with ME-Regen® protein factors that accelerate and direct bone regeneration.
  • Beyond — Cell home® engineered tissues replace the need for permanent implants in indications where regeneration is feasible.
ME-FAB® Form · Mechanical reconstruction Patient-matched Ti-6Al-4V ELI · EBM ME-REGEN® Function · Pharmacological regeneration Low-dose long-acting protein release CELL HOME® Regeneration · Tissue engineering In-vivo tissue manufacturing
Where the Platforms Are Today

A staged commercialisation pathway.

Platform Core Technology Stage Regulatory First Application
ME-Fab® EBM of Ti-6Al-4V ELI with gradient porous micro-architecture Commercialised NMPA Class III · CE-MDR in progress · FDA scoping Cranial reconstruction (DLZ04 / DLZ05)
ME-Regen® Micro-dose protein release platform Pre-clinical Pre-IND / pre-CE Bone & soft-tissue regeneration
Cell home® In-vivo tissue engineering Pre-clinical Pre-IND / pre-CE Bone, cartilage, skin, vascular
Cross-Platform IP

One IP portfolio. Three layers of protection.

60+IP rights total
35Invention patents
2PCT international
15+Patent families